Navigation Links
Drug May Help Colitis Patients Avoid Surgery

Infliximab linked to fewer colectomies in study patients

FRIDAY, Oct. 2 (HealthDay News) -- Treatment with the drug infliximab (Remicade) reduced the need for surgery in ulcerative colitis patients by almost half, a new study found.

Ulcerative colitis causes chronic inflammation of the colon and often leads to surgical removal of the colon (colectomy).

This study included 728 patients who received either an inactive placebo or infliximab for 46 weeks. After one year of follow-up, the researchers found that "treatment with infliximab reduced the need for colectomy by 41 percent compared to patients treated with placebo," lead author and Mayo Clinic gastroenterologist Dr. William Sandborn, said in a Mayo Clinic news release.

The study appears in the October issue of the journal Gastroenterology.

"One of the most feared outcomes for ulcerative colitis patients is surgical removal of the colon. Our research hopes to provide other treatment solutions for patients beyond surgery," Sandborn said.

He provided consulting services for drug maker Centocor during this research. The Mayo Clinic was paid for Sandborn's services.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about ulcerative colitis.

-- Robert Preidt

SOURCE: Mayo Clinic, news release, Sept. 30, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Mouse Study Gives Clues to Colitis
2. New therapeutic targets in the treatment of ulcerative colitis
3. Narrow band imaging colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients
4. Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives
5. Although Remicade and Humira Are Being Increasingly Prescribed for Crohns Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
6. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
7. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
8. A rare case of ischemic colitis caused by chronic venous insufficiency
9. Study underway to find an alternative cure for Crohns disease and ulcerative colitis
10. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
11. Can rectal vitamin E induce remission in patients with mild to moderate ulcerative colitis?
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology: